Biomx Inc
PHGE3.930USD
-0.580-12.72%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
5.54MValor de mercado
PerdaP/L TTM
Mais detalhes de Biomx Inc Empresa
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Informações de Biomx Inc
Código da empresaPHGE
Nome da EmpresaBiomx Inc
Data de listagemDec 18, 2018
CEOSolomon (Jonathan Eitan)
Número de funcionários52
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 18
Endereço22 Einstein St.
CidadeNESS-ZIONA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísIsrael
Código postal7414003
Telefone972723942377
Sitehttps://www.biomx.com/
Código da empresaPHGE
Data de listagemDec 18, 2018
CEOSolomon (Jonathan Eitan)
Executivos da empresa Biomx Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 1 de fev
Atualizado em: dom, 1 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Outro
65.03%
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Outro
65.03%
Tipos de investidores
Investidores
Proporção
Hedge Fund
26.70%
Corporation
12.29%
Holding Company
3.69%
Venture Capital
3.36%
Private Equity
2.50%
Research Firm
1.49%
Individual Investor
1.33%
Investment Advisor/Hedge Fund
0.36%
Investment Advisor
0.23%
Outro
48.05%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
41
528.98K
34.65%
-249.43K
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Deerfield Management Company, L.P.
131.27K
8.6%
--
--
Sep 30, 2025
Cystic Fibrosis Foundation
131.27K
8.6%
+37.18K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
131.23K
8.6%
--
--
Sep 30, 2025
Alyeska Investment Group, L.P.
83.72K
5.48%
+83.72K
--
Sep 30, 2025
Centaurus Investments Limited
56.32K
3.69%
+56.32K
--
Apr 21, 2025
AMR Action Fund LP
46.15K
3.02%
+30.07K
+187.05%
Sep 30, 2024
Telmina Ltd
29.49K
1.93%
+14.54K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
26.85K
1.76%
--
--
Sep 30, 2024
J.P. Morgan Securities LLC
22.63K
1.48%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
